RIGL

Rigel Pharmaceuticals Inc

RIGL, USA

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

https://www.rigel.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RIGL
stock
RIGL

Rigel Pharmaceuticals Reports Promising Phase 1b Study Results TipRanks

Read more →
RIGL
stock
RIGL

With EPS Growth And More, Rigel Pharmaceuticals (NASDAQ:RIGL) Makes An Interesting Case 富途牛牛

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$49.6

Analyst Picks

Strong Buy

1

Buy

1

Hold

4

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

7.17

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

6.85

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

23.72 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very High

11.50 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

34.58 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.06

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 75.94% of the total shares of Rigel Pharmaceuticals Inc

1.

BlackRock Inc

(9.0636%)

since

2025/06/30

2.

Armistice Capital, LLC

(8.9199%)

since

2025/06/30

3.

Morgan Stanley - Brokerage Accounts

(8.4752%)

since

2025/06/30

4.

Vanguard Group Inc

(5.8697%)

since

2025/06/30

5.

Soleus Capital Management, L.P.

(3.6691%)

since

2025/06/30

6.

State Street Corp

(3.346%)

since

2025/06/30

7.

Capitolis Liquid Global Markets LLC

(3.2979%)

since

2025/06/30

8.

Vanguard Total Stock Mkt Idx Inv

(2.9931%)

since

2025/07/31

9.

iShares Russell 2000 ETF

(2.3829%)

since

2025/08/31

10.

Geode Capital Management, LLC

(2.317%)

since

2025/06/30

11.

Marshall Wace Asset Management Ltd

(2.0569%)

since

2025/06/30

12.

Hillsdale Investment Management Inc.

(1.461%)

since

2025/06/30

13.

CM Management, LLC

(1.3937%)

since

2025/06/30

14.

Assenagon Asset Management SA

(1.338%)

since

2025/06/30

15.

Renaissance Technologies Corp

(1.3182%)

since

2025/06/30

16.

SPDR® S&P Biotech ETF

(1.2433%)

since

2025/08/31

17.

Jacobs Levy Equity Management, Inc.

(1.2021%)

since

2025/06/30

18.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0716%)

since

2025/07/31

19.

Bank of America Corp

(1.046%)

since

2025/06/30

20.

Goldman Sachs Group Inc

(1.016%)

since

2025/06/30

21.

Lazard US Sm Cap Eq WW Dist EUR

(0.9815%)

since

2025/05/31

22.

Fidelity Small Cap Index

(0.9813%)

since

2025/06/30

23.

Qube Research & Technologies

(0.9557%)

since

2025/06/30

24.

GlobeFlex Capital, L.P.

(0.9339%)

since

2025/06/30

25.

Macquarie Healthcare I

(0.892%)

since

2025/07/31

26.

Lazard Asset Management LLC

(0.8753%)

since

2025/06/30

27.

Dimensional Fund Advisors, Inc.

(0.8642%)

since

2025/06/30

28.

iShares Russell 2000 Growth ETF

(0.855%)

since

2025/08/31

29.

Scotia Wealth Quant Glbl Sm Cp Eq Pl KM

(0.6478%)

since

2025/07/31

30.

Zacks Small Cap Equity Strategy

(0.6065%)

since

2025/06/30

31.

iShares Biotechnology ETF

(0.5721%)

since

2025/08/31

32.

Fidelity Extended Market Index

(0.5397%)

since

2025/07/31

33.

Vanguard Russell 2000 ETF

(0.4667%)

since

2025/07/31

34.

Nuveen Equity Index R6

(0.4472%)

since

2025/07/31

35.

BlackRock Advantage Small Cap Core Instl

(0.3989%)

since

2025/07/31

36.

State St Russell Sm Cap® Indx SL Cl I

(0.3539%)

since

2025/08/31

37.

First Trust Dow Jones Sel MicroCap ETF

(0.3066%)

since

2025/08/28

38.

American Beacon Small Cp Val R5

(0.2709%)

since

2025/08/31

39.

Janus Henderson Small Cap Gr Alpha ETF

(0.2546%)

since

2025/08/29

40.

Schwab Small Cap Index

(0.2537%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

1.46

EPS Estimate

0.01

EPS Difference

1.45

Surprise Percent

14500%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(10)
GARP
Fair GARP(4.5)
Growth
Moderate Growth(4)
Momentum
Moderate Momentum(6)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(8.5)
Value
Undervalued(7)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.